Evaluation of a coagulation assay determining the activity state of factor VII in plasma by van Deijk, W.A. et al.
  
 
Evaluation of a coagulation assay determining the
activity state of factor VII in plasma
Citation for published version (APA):
van Deijk, W. A., van Dam-Mieras, M. C. E., Muller, A. D., & Hemker, H. C. (1983). Evaluation of a
coagulation assay determining the activity state of factor VII in plasma. Haemostasis, 13(3), 192-197.
https://doi.org/10.1159/000214726
Document status and date:
Published: 01/01/1983
DOI:
10.1159/000214726
Document Version:
Other version
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page
numbers.
Link to publication
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.
Download date: 03 Jun. 2020
Haemostasis ,
Managing Editor: H.C, Hemker, Maastricht
Reprint
Publisher: S.KargerAG, Basel
Print€d in Switzerland
Haemostasis I3: 192-197 (1983) @ 1983 S. KargerAG, Basel030 l-0 147183/0 I 334t92$2.7 5 /O
Evaluation of a Coagulation Assay Determining the
Activity State of Factor VII in Plasma
W.A. van Deijk", M.C.E. van Dam-Mierasb, A.D. Mullerb, H.C. Hemkerb
aDepartment of Internal Medicine, University Hospital Annadal, and bDepartment of Biochemistry,
University of Limburg, Maastricht, The Netherlands
Key Words. Factor VIIa . Factor VII ' Factor Vll-deficient plasma . Cold-promoted
activation . Factor VIla assav
Abstract. A coagulation assay is described that allows the measurement of the degree of
activation of factor VII in circulating blood. The test is based on the use of both bovine and
human brain thromboplastin, together with an artificial factor Vll-deficient plasma. The
latter can be prepared on a relatively large scale which makes it possible to measure factor VII
activation in large series ofpatients.
The determination of factor VII activation during incubation at 4"C of plasma of women
using oral contraceptives shows that the test described adequately measures factor VII acti-
yation. Differences in the time course of factor VII activation during this incubation in glass
and plastic containers are found and implicate that rigorous standardization of blood sam-
pling and test conditions is necessary. A possible mechanism that causes this critical depen-
dence upon the test conditions is discussed.
Introduction
In the preliminary phase of an epidemio-
logical investigation of the activation of coag-
ulation enzymes in the circulating blood of
cancer patients we critically assessed the fac-
tor VII activation test describedby Hemker
et al. [6]. The test system described allows the
measurement of the degree of activation of
factor VII in plasma and is based on the use
of both bovine and human brain thrombo-
plastin, together with an artifrcial factor VII-
deficient reagent. The latter can be prepared
on a relatively large scale which makes it pos-
sible to measure factor VII activation in a
large series of patients. This may be of im-
portance because of the possible epidemio-
logic use of this estimation [2, 9].
The usefulness of the test was assessed by
the measurement of factor VII activation
during incubation at 4'C of pooled plasma
of women using oral contraceptive agents
(OCAs) [4]. Because differences in the time
course of activation of factor VII in plasma
during incubation in the cold in glass and
plastic containers have been reported in the
literature 14, 5, l2l we also investigated this
aspect.
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It will be shown that the test system de-
scribed adequately measures factor VII acti-
vation and that, because of the influence of
the incubation conditions upon the degree of
factor VII activation, rigorous standardiza-
tion of the blood sampling and test proce-
dures is highly necessary.
Materials and Methods
Factor Vll-Deficient Reagent. An artificial factor
Vll-deficient reagent was prepared by a modification
of the method of Lechner and Deutsch [6]. The artifi-
cial reagent contained: 640lo human factor X, 72o/o
bovine factor Y, 74o/o human factor ll and 2.25 g/1
fibrinogen. The results obtained with this reagent
showed a perfect correlation with those obtained with
congenitally factor Vll-defrcient plasma [6]. The fac-
tor VII concentration ofthe reagent was 1.68 0/0, deter-
mined as described earlier [6].
Thromboplastirs. Human and bovine thrombo-
plastins were prepared by a modification of the
method of Owren and Aas flIl.
Buffer. Yeronal/acetate (0.15 M, p}J7.4).
Sampling Procedure. Blood was obtained by veni-
puncture after as short a period of stasis as possible
and was collected in plastic tubes containing sodium
citrate.2H2O (final concentration 10 mily'). The first
few milliliters of blood were discarded. Plasma was
prepared by centrifugation of blood for 10 min at
3,000 g and the supernatant for 30 min at 12,000 g to
bring the platelets down. During blood sampling and
plasma preparation procedures only plastic materials
were used. Platelet-free plasma was pooled and stored
in l-ml portions at -20 " C for 24 h prior to testing.
Incubation at 4'C. Immediately after thawing,
plasma samples were kept at 4oC in plastic or glass
tubes. After 0, 1,2, 4,24, and 48 h, samples were tak-
en, diluted in buffer and screened for factor VII acti-
vation.
Determination of Factor VII Activation. Diluted
plasm.a sample (0.1 ml), factor Vll-deficient reagent
(0.1mI) and human or bovine thromboplastin
(0.1 ml) were incubated during 30 s in a glass tube at
37 "C. The coagulation was initiated by the addition
of 0.1ml CaClu (33 mtr/) ard the coagulation time
recorded. All determinations were carried out in du-
plicate. The degree of factor VII activation in the test
plasma was determined by the ratio of plasma factor
VII level determined with bovine thromboplastin
over that of plasma factor VII level determined with
human thromboplastin as has been suggested pre-
viously [7].
Reference Tables. Coagtrlation times obtained
when dilutions of pooled normal human plasma are
used as a source offactor VII in a factor Vll-deficient
medium and tested vrith either human or bovine
thromboplastin were used to construct the reference
curves (table I). From these curves reference tables can
be derived which makes it possible to determine the
factor VII concentration in test plasma in a well-
delined range, set by the standard concentrations used
to construct the reference tables and even slightly
beyond [6].
Results
In figure I the results of the experiments
in which plasma from women using OCAs
was incubated at 4'C under diflerent experi-
Table I. Coagulation times obtained with normal
human plasma incubated in glass at 37 'C with human
or bovine thromboplastin (TP) in a factor VII-defi-
cient reagent
Plasma
concentration
o/o v/v
Coagulation times
human TP bovine TP
20
1 0
5
2 .5
- t . o /
1 .25
1.00
0.  s0
21.8
26.6
32.0
38.0
4t.7
45.3
48.5
57 .7
71 .0
46.3
54.0
64.8
I  ) - )
80.3
87 .8
86 .1
90.5
96.6
SD 1.00/0. Minimal time: with human TP 18.8 s:
with bovine TP 34.6 s.
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mental conditions are shown. As can be seen
in this figure, the amount of factor VII mea-
sured with the test system using human
thromboplastin changes appreciably less dur-
ing the incubation at 4"C than the apparent
amount of factor VII measured with the test
using bovine thromboplastin does. It can fur-
ther be concluded that, although the time
course of factor VII activation during incuba-
tion in glass and plastic containers is differ-
ent, the ultimate stage of factor VII activa-
tion is the same in both materials. Further-
more, the curves obtained with diflerent
sample dilutions are approximately parallel.
As the samples containing relatively high
plasma concentrations (5 or 10o/o) produce
extremely short coagulation times which fall
beyond the validity range of the reference
tables [6], coagulation times instead of factor
VII levels had to be used on the ordinates in
frgure l. In test samples that contain a lower
amount of plasma the factor VII concentra-
tion can be determined in the usual way. In
the figures 2 and 3 the apparent increase in
factor VII concentration in plasma of women
using OCAs during incubation at 4'C in
glass as determined with human and bovine
thromboplastin respectively is shown. In the
figures 4 and 5 the same experiment is de-
picted for the incubation in plastic. As would
be expected from earlier observations, the
apparent increase in factor VII activation
during incubation in the cold was very pro-
nounced when assayed with bovine thrombo-
plastin and much less evident when assayed
with human thromboplastin [7]. As will be
discussed below, the stage of activation of
factor VII in plasma can best be expressed by
the use of the ratio (frg.6,7):
Factor VII estimated with bovine thromboplastin
.
H 1.0 ' /o
H 1 .67" t .
e  2 .5 ' l '
<- 5.0"L
r- 10.0"L
30
10
0
Fig.1. Shortening of the one-stage test for factor
VII in several plasma dilutions during incubation in
the cold in plasma of women using OCAs. In A and B
incubation was done in glass, and in D and C in plas-
tic. In A and C human thromboplastin was used in the
test mixture, while in B and D bovine thromboplastin
was used.
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Fig. 2. Activation of factor VII in the cold duiing
incubation of plasma in glass, measured with human
brain thromboplastin in several plasma dilutions.
Fig. 3. Activation of factor VII in the cold during
incubation of plasma in glass, measured with bovine
brain thromboplastin in several plasma dilutions.
Fig.4. Activation of factor VII in the cold during
incubation of plasma in plastic, measured with human
thromboplastin in several plasma dilutions.
Fig. 5. Activation of factor VII in the cold during
incubation of plasma in plastic, measured with bovine
thromboplastin in several plasma dilutions.
Fig.6. Factor Vlla/factor VII ratio during incuba-
tion of plasma in glass, measured in several plasma
dilutions.
Fig.7. Factor Vlla/factor VII ratio during incuba-
tion of plasma in plastic, measured in several plasma
dilutions.
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Discussion
As was shown previously by Hemker etal.
[7], bovine thromboplastin, in contrast with
human thromboplastin, is hardly able to in-
teract with human factor VII unless this fac-
tor has been previously activated. Although
the exact initiation of the activation of the
extrinsic pathway is still unknown [4], this
might be explained by assuming that the acti-
vation step of factor VII and not the combi-
nation step between thromboplastin and fac-
tor VII is rate limiting [0, l5]. Therefore, it
must theoretically be possible to measure the
state of activation of factor VII in plasma by
exploring this difference in activity between
thromboplastins from different species. The
results presented here confirm this idea.
It is shown that a test system using bovine
thromboplastin measures an enormous in-
crease in factor VII activity during incuba-
tion at 4"C, a situation which is known to
produce factor VII activation. The test sys-
tem using human thromboplastin, however,
only shows a small increase in factor VII
activity under these conditions, showing that
the test is not completely independent of the
activity state of factor VII in the sample.
This means that the sample handling, be-
cause it is known to influence factor VII acti-
vation, is compulsory to be rigorously stan-
dardized. In order to obtain a figure that is
predominantly dependent upon the activa-
tion state of factor VII rather than upon the
absolute amount of this factor present we
propose to use the quotient of the activities
obtained with bovine and human thrombo-
plastin respectively.
Recently a new coupled amidolytic assay
for factor VII has been described [3, 13]. The
authors could determine the activation state
offactor VII by the use ofa coagulation assay
in which human thromboplastin was used to
initiate the coagulation reaction next to an
amidolytic assay. The quotient of these activ-
ities indeed will vary with the activation state
of factor VII, but, as human thromboplastin
in a coagulation assay is relatively unsensi-
tive to factor VIIa, we prefer the assay based
upon the use of coagulation assays with
bovine and human thromboplastin. The
methods described need the availability of
purified factor X, which may be a practical
difficulty in most clinical laboratories. The
spectrophotometric factor VII determination
by Avvisati et al. [1] employs congenital fac-
tor Vll-deficient plasma which is not abun-
dantly available either. We therefore propose
that the determination of the factor VII ac-
tivation state by the use of coagulation as-
says with bovine and human thromboplastin
is at the moment the most practical solution.
The three methods are presently being com-
pared lvan Dieijen and Osterud, pers. com-
mun.l.
Our results, showing the differences in the
time course of factor VII activation during
incubation in the cold in glass and plastic,
confirm the results that have been reported in
the literature 14,5,l2l. The ultimate stage of
factor VII activation proved to be the same
in both materials. The different mechanisms
for factor XI in the binding to glass and plas-
tic materials as described by Mannhalter and
Schiffman [8] might also apply to factor XII
and kallikrein, leading to their slower activa-
tion in plastic compared to glass. As these
factors are known to play an important role
in the cold-promoted activation of factor VII
15, l2l, it is tempting to assume that similar
mechanisms might play a role in the slower
activation of factor VII in plastic compared
to glass. Recent experiments show that be-
sides factor XII, factor II might also play a
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role in the cold-promoted activation of factor
YII lvan Deijk, in preparationl.
In conclusion we can say that the test sys-
tem described adequately measures the factor
VII activation state and that, because of the
influence of experimental conditions upon
the degree of factor VII activation, rigorous
standardization of blood sampling and test
procedures is necessary.
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